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Abstract
We describe the rudolph mouse, a mutant with striking defects in both central nervous system and skeletal development.
Rudolph is an allele of the cholesterol biosynthetic enzyme, hydroxysteroid (17-beta) dehydrogenase 7, which is an intriguing
finding given the recent implication of oxysterols in mediating intracellular Hedgehog (Hh) signaling. We see an abnormal
sterol profile and decreased Hh target gene induction in the rudolph mutant, both in vivo and in vitro. Reduced Hh signaling
has been proposed to contribute to the phenotypes of congenital diseases of cholesterol metabolism. Recent in vitro and
pharmacological data also indicate a requirement for intracellular cholesterol synthesis for proper regulation of Hh activity
via Smoothened. The data presented here are the first in vivo genetic evidence supporting both of these hypotheses,
revealing a role for embryonic cholesterol metabolism in both CNS development and normal Hh signaling.
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Introduction
Hedgehog (Hh) ligands have numerous and fundamental roles in
both embryonic development [1,2] and tumor biology [3].
Mammalian hedgehog proteins bind to the transmembrane
receptor Patched (Ptc) and thereby relieve its repression of Smoothened
(Smo). Intracellular transduction of Smo activity requires processing
of GLI proteins. The primary cilium has shown to be an essential
structural component for proper Hh signaling in mammals with
dynamic localization of Ptc in response to binding of Sonic
hedgehog (SHH; [4,5,6,7]). Functional SHH signaling requires
removal of PTC from the cilium, translocation of SMO to the
cilium, and activation of SMO by an as yet unknown mechanism
[5,6,8,9].
It has been well established that cholesterol is an essential
component of Hh signal transduction. Processing of the Hh ligand
in the producing cell includes the covalent modification of
cholesterol to the carboxyl end of the immature protein. Although
cholesterol in Hh proteins is thought to facilitate the proper
dispersal of SHH through the target field, it is not necessary for
signal transduction [7]. More recently, however, metabolites of
cholesterol and cholesterol biosynthetic pathway intermediates
have been shown to have an intracellular role in SHH signal
transduction. For example, pharmacological inhibition of choles-
terol biosynthesis leads to defective responses to SHH ligand,
independent of SHH processing, both in vitro and in vivo, with the in
vivo effect mimicking Shh loss of function phenotypes [10,11,12].
Moreover, not only can cholesterol-derived oxysterols activate the
Hh pathway in vitro [13], but treatment of cells with oxysterols has
been shown to cause translocation of PTC and SMO to the cilium
in the absence of SHH ligand [8].
Mutations in enzymes required for cholesterol biosynthesis are
associated with a number of human diseases [14]. The best
known is Smith-Lemli-Opitz Syndrome, in which patients have
central nervous system (CNS) malformations, including holopro-
sencephaly and microcephaly, and skeletal defects (most often
postaxial polydactyly) caused by mutations in 7-dehydrocholesterol
reductase (DHCR7) [15]. Other disorders of cholesterol biosyn-
thesis include desmosterolosis, lathosterolosis, X-linked dominant
chondrodysplasia punctata (CDPX2), CHILD syndrome (con-
genital hemidysplasia with icthyosiform erythroderma or nevus
and limb defects) and Greenberg skeletal dysplasia. Overlapping
features of these disorders include abnormalities in the CNS,
facial dysmorphisms, and skeletal defects, often including
polydactyly or other digit patterning defects. Mouse models also
exist for many of these disorders and have similar defects. The
frequent occurrence in these human syndromes and mouse
mutants of defects in neurodevelopment, craniofacial morpho-
genesis and skeletal growth and patterning has led to the proposal
that abnormal Hh signaling may be the root cause of these
embryological defects. This speculation is based principally on
genetic experiments that have shown a role for Hh signaling in
the development of all of these tissues, and the known role of
sterol metabolism in Hh signal transduction. Despite this, there is
relatively little direct evidence from these mouse models for a
defect in Hh signaling.
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ethyl-nitrosourea (ENU)-induced mutation in hydroxysteroid (17-
beta) dehydrogenase 7 (Hsd17b7), which was the last enzyme of the
cholesterol biosynthetic pathway to be identified and one of four
proteins of the sterol-4-demethylase complex [16]. Rudolph mutants
have severe developmental abnormalities in several tissues
including the brain and appendicular skeleton. We find that
tissues from rudolph mutants have an abnormal sterol profile
consistent with impaired activity of the sterol-4-demethylase
complex. We further demonstrate that the rudolph mutant has
deficient responses to Hh signaling, both in vivo and in vitro. These
results support the recently proposed model that functional
intracellular sterol metabolism is required for proper cilia-
mediated activation of the Hh signaling pathway.
Results
Rudolph mutants show defective growth and patterning
of the CNS and appendicular skeleton
We recently recovered the rudolph mutation via an ENU
mutagenesis screen designed to identify recessive mutations
affecting development of the mammalian forebrain. Rudolph
mutants were first ascertained by a blood spot on the end of the
nose and their abnormally curved forelimbs (Figure 1B). The
precursor to this nasal phenotype was sometimes evident at earlier
stages as a blebbing of the craniofacial epithelium (Figure S1A).
Examination of the embryonic skeleton revealed that all long
bones of the appendicular skeleton were significantly shorter than
those of wild-type littermates while the axial skeleton and ribs
appeared normal. (Figure 1D, Figure S2, Table S1). Further
analysis of the embryos revealed severe defects in CNS
development. The telencephalic tissue was markedly reduced in
size and highly disorganized in mutants at embryonic day (E) 16.5
(Figure 1F, 1H). Mutants had a smaller neurogenic ventricular
zone and clumps of cells in the developing cortical plate. Similar
defects were seen in the E16.5 retina and spinal cord (Figure 1J,
Figure S3B). Initial cortical morphogenesis appeared largely
normal (Figure S3D, S3F).
To further characterize the rudolph phenotype, we performed a
molecular analysis of the cortical phenotype. We assessed cell
proliferation at E14.5 by BrdU treatment of pregnant dams or
immunostaining of embryos with Ki67 and found a marked
decrease in proliferation in mutants (Figure 2B). Some of the
mitoses we detected were seen as foci of BrdU-positive cells (inset
in Figure 2B). We thus interpreted the clusters of cells seen
histologically in the rud cortex to be neurogenic foci. To determine
the cause of the reduced neuronal tissue, we assayed apoptosis at
E14.5 using the TUNEL reaction and found increased levels of
cell death in the mutant tissue, distributed throughout the cortex
and enriched along the ventricular surface (Figure 2D). An
increased level of cell death was not seen in non-neural tissue (data
not shown). Decreased, disorganized neuronal proliferation and
increased cell death were also evident at E12.5 (data not shown).
Immunohistochemistry for TuJI to identify differentiated neurons
at E14.5 showed a marked decrease in differentiation in mutants
compared to wild-type (Figure 2F). In addition, foci of TuJI
immunoreactivity appeared in regions of no differentiation,
consistent with the disorganization of the cortex seen histological-
ly. Disorganized proliferation was also evident in the developing
rudolph retina, where we observed similarly abnormal neuronal
differentiation, decreased cell proliferation and increased apopto-
sis, but at different stages of development. Whereas at E12.5 we
saw no significant decrease in proliferation or apoptosis between
wild-type and mutant (Figure 2H; data not shown), at E14.5 we
found a decrease in BrdU incorporation in the mutant retina
(Figure 2J) and an increase in apoptosis (Figure 2L). Furthermore,
the pattern of neuronal disorganization we saw in the rud cortex
was similarly evident in the rud retina at E14.5 (Figure 2N).
Genetic background affects the rudolph phenotype
The phenotypes of the rudolph mutants exhibit a variability in
severity that appears to be dependent on genetic background. For
example, we noted increased blebbing on the developing head and
limbs in embryos that came from a mixed background (Figure
S1B–S1D). Embryos from our ENU screen have a mixed genetic
background with contributions coming from both A/J (the
mutagenized strain) and FVB mice (introduced as part of the
outcross for mapping purposes). In this A/J; FVB background,
embryos were recovered in approximately Mendelian ratios from
E10.5–E18.5 (Table S2). No mutants have been recovered after
birth, suggesting they are among the stillborn fetuses. Upon
introducing the B6 background, the number of mutant embryos
did not decrease significantly, but we then began to see a number
of dead embryos from E11.5 and older (7.8%), an increase in the
severity of the nasal blebbing (Figure S1A–S1C: 14.8%) and limb
patterning defects (10.4%). Further introgression into the B6
background resulted in no significant decrease in recovery of
mutant embryos but a large increase in the incidence of more
severe blebbing (48.5% in pooled N1, N2, and N3B6 mice).
Backcrossing to FVB rescued this defect, and blebbing is essentially
absent in N3 FVB mice. The reduced fecundity of 129 mice
limited our analysis of this genetic background, preventing any
definitive comments on modifiers on the 129 background (Table
S2).
Hsd17b7 is the gene mutated in rudolph embryos
We initially mapped the rudolph mutation to Chromosome 1
using a whole-genome 768-marker single nucleotide polymor-
phism (SNP) panel [17]. Examination of the 255 predicted and
known genes in the region suggested Hsd17b7 as a candidate for
further analysis because of its known function in cholesterol
metabolism and its reported expression pattern in limb buds and
Author Summary
The molecules and signaling pathways that regulate
growth and patterning of the developing embryo are still
being elucidated, and one valuable experimental approach
is the use of animal models, such as the mouse. We have
identified a recessive mutation in the mouse, rudolph, that
causes abnormal forebrain development and have deter-
mined that the mutated gene encodes hydroxysteroid (17-
beta) dehydrogenase 7 gene, an enzyme necessary for
cholesterol biosynthesis. Cholesterol is essential for proper
signal transduction of the hedgehog family of proteins, key
regulators of both developmental biology and tumor
progression. We show that hedgehog signaling is dimin-
ished in our rudolph mutant. Our conclusions from
studying this mouse mutant support two recent hypoth-
eses in developmental biology. First, several human
malformation syndromes are known to be caused by
defects in cholesterol metabolism, but support linking the
malformation to abnormal hedgehog signaling has not
definitively been made. Second, while in vitro studies have
shown that proper levels of metabolic by-products of
cholesterol are necessary for proper hedgehog signaling,
our studies offer the strongest genetic animal model
evidence to support this idea.
Hedgehog Signaling In Vivo Requires Hsd17b7
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revealed a point mutation in the sixth intron, 27 base pairs
upstream of the intron-exon boundary (Figure 3A). We analyzed
transcripts by RT-PCR with primers spanning exon 7 and found
the predominant PCR product in mutant tissue to be smaller than
that of wild type (Figure 3B). Sequencing of this product revealed a
precise excision of the seventh exon in the smaller PCR species.
The loss of exon 7 was confirmed with primers in the sixth and
seventh exons (Figure 3C). Interestingly, a small amount of this
truncated transcript was present in wild-type cDNA, and,
conversely, mutant tissues retained a very small fraction of the
wild-type transcript (Figure 3B, 3C). We hypothesize that these
RT-PCR products represent two naturally occurring forms of the
Hsd17b7 transcript and that the rudolph ENU mutation affects the
ratio of their abundances. The phenotypes we observe in the
rudolph mutants appear to be somewhat tissue specific and have
differing expressivity in different strains. However, the variation in
the cDNA splicing pattern does not differ among different tissues
examined (heart/lung, limbs, brain, or whole embryo) or depend
on varying genetic backgrounds, suggesting that tissue specific
transcription and variation in genetic background account for the
variability in phenotype (Figure S1E).
Loss of the seventh exon of HSD17B7 is predicted to encode a
protein with an in-frame deletion of 19 amino acids. To assess the
effect of this splicing mutation, we tested HSD17B7 expression by
Western immunoblot analysis and found only trace levels of
protein in mutant tissue lysates (Figure 3D). Although the deleted
seventh exon is part of a putative endoplasmic reticulum
anchoring sequence, in vitro expression of a rud-GFP fusion protein
results in deficient protein rather than mislocalization, suggesting
that the rudolph deletion generates an unstable protein product
(Figure S4). Embryos homozygous for a null allele of Hsd17b7
generated from a 129 genetic background do not survive past
E10.5, suggesting the rudolph allele is likely a hypomorph [18,19].
Figure 1. Phenotypic characterization of rudolph mutants. Rudolph mutants (B) are readily distinguishable from wild-type (A) littermates at
E16.5 by their shortened, curved forelimbs. Some mutants have accumulations of blood in nasal blebs (B). Skeletal preparations of E16.5 limbs show
significantly shorter long bones in mutants (D). The mutant forebrain at E16.5 (F) is severely affected with a reduction in tissue throughout. Cleft
palate is also noted in mutants (arrow in F). While the wild-type cortex (G) has a readily identifiable ventricular zone (vz), intermediate zone (iz), and
cortical plate (cp), closer examination of the dorsal cortex in the mutant reveals significant disorganization (H). Similar disorganization is seen in the
rud retina (J).
doi:10.1371/journal.pgen.1002224.g001
Figure 2. Telencephalic and retinal development are abnormal in rudolph mutants. (A,B) BrdU labeling and immunohistochemistry shows
a significant decrease in dividing cells in the rudolph cortex (A) as compared to the wild-type (A). The inset in B highlights the groups of dividing cells
sometimes seen away from the ventricular zone. (C,D) Analysis of cell death using the TUNEL assay reveals a large increase in cell death in mutant
tissue (B) with an enrichment of the death at the ventricular surface. (E,F) Neuronal differentiation as measured by TuJI immunohistochemistry is
dramatically decreased in rud mutants (F). (G,H) BrdU labeling at E12.5 does not indicate a significant difference in rates of cell division in the rudolph
retina at E12.5, but a significant decrease is seen at E14.5 (J). Similar to cortical development, the decreased proliferation is accompanied by an
increase in apoptosis as shown by the TUNEL assay (K,L). Neuronal differentiation in the mutant retina is disorganized in mutant tissue (M) as
compared to wild-type (N).
doi:10.1371/journal.pgen.1002224.g002
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mutation in the intron of rudolph mutants between the sixth and seventh exons. (B,C) RT-PCR analysis of wild-type and mutant transcripts with
primers for exons 6–8 of the rudolph transcript give two PCR products. The larger species is found in low quantities in the rud mutant tissue. A smaller
species, which lacks the seventh exon, was also amplified. RT-PCR with primers for the sixth and seventh exon results in very little amplification of
mutant cDNA. (D) Immunoblotting from embryo lysates shows very little protein in rudolph mutants as compared to wild-type.
doi:10.1371/journal.pgen.1002224.g003
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We analyzed the sterols present in liver and brain tissue from
wild-type, heterozygous, and rudolph embryos at E12.5 by gas
chromatography-mass spectrophotometry (Figure 4) and found
marked differences between wild-type and mutant tissues. The
identified abnormalities in methylsterol abundances are consistent
with reduced function of the Hsd1b7 enzyme in rudolph brain tissues
(Table 1). Sterol species upstream of Hsd17b7 activity were
present in increased amounts, the most prominent of which were
the HSD17B7 substrates zymosterone and 4methyl-zymosterone,
and a third ketosterol tentatively identified as methylcholest-7-en-
3-one. Various mono- and dimethylsterols that do not normally
accumulate in wild-type tissues were also present in increased
amounts, including 4a-methyl-5 a-cholest-8-en-3b-ol, 4 a-methyl-
5 a-cholest-7-en-3 b-ol, 4 a-methyl-cholesta-8(9),24-dien-3 b-ol,
and 4,4-dimethyl-5 a-cholest-8(9),24-dien-3 b-ol. Desmosterol, a
compound downstream of Hsd17b7, was reduced. The predom-
inance of zymosterone (5 a-cholesta-8,24-dien-3-one) and 4 a-
methylzymosterone in the brain compared to liver is in keeping
with the known decreased activity of desmosterol reductase in the
brain, especially fetal brain, and the retention of the 24-unsturated
bond in certain sterol species in the normal brain. In wild-type
brain, desmosterol (5 a-cholesta-5,24-dien-3b-ol) is the most
abundant 24-unsaturated sterol.
Hedgehog signaling is disrupted in the rudolph mutant
central nervous system
In view of the important role of Hh signaling in patterning of the
limbs, face, and brain, and the genetic and cellular evidence for a
role of cholesterol metabolism in this pathway, we hypothesized
that Hh signaling is perturbed in the rudolph mutant. Furthermore,
recent evidence specifically implicates intracellular sterols in the
regulation of the subcellular localization of the Hh signaling
components, Patched and Smoothened, supporting the possibility
that an abnormal sterol profile in rudolph mutants could disrupt Hh
signaling [5,6,8]. To assess this, we generated mice homozygous
for the rudolph mutation that carried the Patched-lacZ gene, a
transcriptional target of Gli2 and thus a reporter of Shh signaling
activity. In these embryos, we found reduced levels of Ptc-lacZ in
the developing brain at both E11.5 and E14.5 (Figure 5B, 5D;
Figure S5; data not shown). We also noted decreased expression of
another Shh target gene, Gli1, in the retina and brain of rudolph
mutants at E14.5 (Figure 5F, Figure S5). Furthermore, analysis
using quantitative RT-PCR demonstrated reduced Ptc mRNA in
Figure 4. Sterol profiles. Brain (A,B) and liver (C,D) tissue from wild-type (A,C) and rudolph (B,D) E14.5 embryos were used to create sterol profiles
by gas chromatography-mass spectrometry. Some compounds identified include lanosterol (a), zymosterone (b), 4a-methyl-zymosterone (c),
desmosterol (d), lathosterol (e), cholesterol (f), 4a-methyl-5a-cholest-8-en-3b-ol (g), 4a-methyl-5a-cholest-7-en-3b-ol and 4a-methyl-cholesta-8(9),24-
dien-3b-ol (h), 4,49-dimethyl-5a-cholest-8-en-3b-ol (i), 4,4-dimethyl-5a-cholest-8(9),24-dien-3b-ol (j), and methylcholest-7-en-3-one (tentative) (k).
doi:10.1371/journal.pgen.1002224.g004
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p=0.053, data not shown). All tissues with reduced SHH target
gene expression have severe morphological abnormalities in the
rudolph mutant and are known sites of Hh signaling. Because dorsal-
ventral patterning of the neural tube also requires SHH signaling,
we examined the dorsal-ventral character of the rudolph neural tube
and found that, at both E10.5 (Figure S6A–S6N) and E12.5
(Figure S6O–S6BB), all immunohistochemical markers for cell fate
we tested showed normal patterns of expression along the dorsal-
ventral axis of the rudolph neural tube.
Hedgehog signaling is disrupted in the rudolph mutant
skeleton
We also observed limb patterning defects in mice from a mixed
A/J, FVB, B6 (Figure 6A, 6B, Table S2). As Hh signaling is
important for proper patterning, we examined Hh signaling in the
developing limb bud. Normal patterning of the limb results in
elevated Shh signaling in the posterior portion of the developing
limb bud as compared to the anterior. We observed Ptc expression
in rud mutants (n=3) from a mixed background using both Ptc-lacZ
expression and whole mount in situ hybridization and found one
embryo with reduced Ptc expression in the posterior limb bud
(Figure 6D) as compared to littermate control (Figure 6C). The
variable penetrance of the limb patterning phenotype is consistent
with an incompletely penetrant reduction in Shh activity in the
developing limb bud. Hh signaling is also involved in long bone
growth (where the relevant ligand is Indian hedgehog). We also see
reduced expression of Ptc in the developing limb of rud mutants
using either the Ptc-lacZ allele (Figure 6F) or an in situ riboprobe
for Ptc (Figure 6H).
Hedgehog signaling is reduced in vitro upon reduction
of Hsd17b7
To further determine if Hsd17b7 expression affects SHH
signaling, we generated primary mouse embryonic fibroblasts
(MEFs) from wild-type and rudolph embryos and assessed their
response to added SHH protein. In wild-type MEFs, treatment
with SHH protein resulted in increased cell proliferation and
increased Ptc and Gli mRNA levels, which is consistent with the
known role of SHH as a mitogen in several systems and with Ptc
and Gli being direct targets of SHH signaling. In contrast, the
effects of SHH treatment were blunted in mutant cells (Figure 7A–
7C). We also generated MEFs from wild-type;Ptc-lacZ and
rudolph;Ptc-lacZ embryos to measure SHH transcriptional activity
via the accumulation of b-galactosidase. In this assay, wild-
type;Ptc-lacZ MEFs responded to SHH treatment with increased
b-galactosidase production, whereas rudolph;Ptc-lacZ MEFs did not
(Figure 7D). Together these data suggest that rudolph mutant mice
have reduced intracellular signal transduction distal to the binding
of SHH ligand in the SHH signaling cascade.
In a parallel approach, we used Pzp53MED cells [20], which
are SHH-responsive cells carrying the Ptc-lacZ allele, to assess the
role of Hsd17b7 in SHH signal transduction. We used lentiviral
infection followed by clonal selection with plasmids for RNAi
knockdown of Hsd17b7 to create cell lines with reduced levels of
Hsd17b7 (approx. 80% reduced, data not shown) and then treated
the lines with recombinant SHH, as done with the MEFs. Two
independent RNAi clones did not induce significant b-galactosi-
dase production upon SHH treatment while the control cell line
responded robustly (Figure 7E).
Smoothened localization to the primary cilium is
unaffected in the rudolph mutants
The decreased response to SHH protein in vitro shows that the
signaling defect is downstream of ligand binding to cell surface
receptors. Recent data have shown that treatment with oxysterols
can cause a change in the subcellular localization of PTC and
SMO protein [8], which is necessary but not sufficient for
activation of the SMO protein [6,21]. The Hsd17b7 phenotype
may be caused by dysregulated sterol biosynthesis affecting the
localization and/or active state of the Smo receptor. We therefore
examined the localization of a SMO-GFP fusion protein in wild-
type and rudolph MEFs upon treatment with SHH, but found no
decreased mobility of the SMO-GFP to the cilia in the mutant
MEFs (Figure 8). Wild-type MEFs without SHH treatment had
SMO-GFP throughout the primary cilia in only a subset of cells
examined (43.3%: n=29/67 ciliated, transfected cells in two
independent experiments). Upon addition of SHH, SMO-GFP
was found throughout the cilium in the majority of cells examined
(89.6%; 65/73 cells). Mutant MEFs behaved similarly, with
untreated cells having 38.7% SMO-GFP positive cilia (24/62) and
SHH treatment leading to 86.7% (72/83) of cells with SMO-GFP
throughout the cilium. In addition to the increase in cells with
SMO-GFP throughout the cilium upon SHH treatment, we also
note that untreated cells often had SMO-GFP largely at the base
of cilium. SHH treatment resulted in very few cells showing SMO-
GFP localization to the base of the cilium, but rather throughout
the length of the cilium. Taken together, these data suggest that
the rudolph mutation does not affect the localization of SMO within
the primary cilium in response to SHH treatment.
Discussion
In this report, we describe the rudolph mouse mutant phenotype,
which is caused by a mutation in the cholesterol biosynthetic
enzyme Hsd17b7, the 3-ketosteroidreductase element of the sterol-
4-demethylase complex. The rudolph phenotype includes marked
abnormalities in the development of the nervous system and
appendicular skeleton, which correlate with a decreased effective-
ness of SHH signaling both in vivo and in vitro. Because sterols have




Lanosterol (a) 0.19 0.30
4a-methyl-5a-cholest-8-en-3b-ol (g) 0.13 5.86
4a-methyl-5a-cholest-7-en-3b-ol (h) 0.04 0.58
4a-methyl-cholesta-8(9),24-dien-3b-ol 0.31 1.95
4,49-dimethyl-5a-cholest-8-en-3b-ol (i) 0.03 0.44
4,49-dimethyl-5a-cholest-8(9),24-dien-3b-ol (j) 0.49 2.16
methylcholest-7-en-3-one (k)* 0.000 7.164
Substrates of Hsd17b7
Zymosterone (b) 0.000 2.185
4a-methylzymosterone (c) 0.021 14.787
Downstream of Hsd17b7
Desmosterol (d) 15.65 1.07
Cholesterol (f) 80.48 59.88
Sterols levels are quantified as percent of total sterols in tissue. Values from
heterozygous embryos were very similar to those found in wild-type.
*Tentative identification.
doi:10.1371/journal.pgen.1002224.t001
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movement of SMO to the primary cilium in response to SHH
protein and found no defect in SMO trafficking. This suggests that
the abnormality in rudolph affects the activation of SMO, resulting
in a decreased response to SHH ligand binding.
Sterols in rudolph mutants
Our study of the sterols present in brain tissues from the mutant
mice is consistent with reduced Hsd17b7 enzymatic function, as we
observe an increase in compounds of the cholesterol biosynthetic
pathway upstream of the Hsd17b7 enzyme. While no patient has
yet been identified with a defect in Hsd17b7, increased levels of
mono and dimethyl sterols have been reported in plasma and/or
skin of patients with mutations in two other genes of the sterol-4-
demethylase complex, SC4MOL (sterol C4-methyloxidase like) and
NSDHL (NAD(P)H steroid dehydrogenase-like protein) [22,23].
To explain the phenotype of the rudolph mouse we considered
several possible metabolic effects, including 1) a decrease in the
cellular level of cholesterol, 2) a decreased level of another product
of Hsd17b7 enzymatic function, and 3) teratogenic effects of high
levels of the cholesterol precursors detected in our study. Several
lines of evidence suggest the last to be the major cause of the
phenotype we observe. If simply a deficiency of the end-product,
cholesterol, caused the rudolph phenotype, one might expect mice
carrying mutations in the cholesterol biosynthetic pathway to
resemble each other. This is not the case, since, despite some
phenotypic overlap in adjacent disorders in the pathway, overall
there are significant phenotypic differences across the spectrum of
mouse models of human cholesterol biosynthetic disorders [24].
The best-characterized disorder of cholesterol biosynthesis is
Smith-Lemli-Opitz syndrome [25,26], caused by mutations in
DHCR7, which encodes the 7-dehydrocholesterol reductase that
converts 7-dehydrocholesterol to cholesterol [15,27,28]. Two
mouse models with null alleles of Dhcr7 have abnormal phenotypes
including cleft palate, but lack the striking brain phenotypes we
found in the rudolph mutant [29,30]. The Dhcr7 mutant mice have
decreased cholesterol and increased 7-dehydrocholesterol levels in
serum and tissues [29]. The enzyme immediately preceding
DHCR7 is SC5DL (sterol C5-desaturase-like) which is deficient in
human patients with lathosterolosis [31]. A null Scd5 allele in the
mouse is a neonatal lethal with craniofacial and limb defects and
decreased cholesterol similar to those of the Dhcr7-deficient mouse,
but with increased levels of lathosterol (the substrate of Sc5d) in all
tissues [32]. Given that the Dhcr7 and Scd5 mouse models have a
significant decrease in cholesterol levels, which is not apparent in
the rudolph mutant, and that their phenotypes do not resemble the
rudolph phenotype, we conclude that cholesterol deficiency does not
cause the distinctive embryological abnormalities of the rudolph
mouse.
Nsdhl, another element of the sterol-4-demethylase complex, is
the enzyme immediately preceding Hsd17b7 in the canonical
cholesterol biosynthetic pathway [33]. NSDHL mutations in
humans cause CHILD syndrome (congenital hemidysplasia with
ichthyosiform erythroderma and limb defects), a rare X-linked
dominant disorder with presumed lethality for CHILD causing
alleles [34] and, with hypomorphic NSDHL mutations, CK
syndrome, a form of X-linked mental retardation [22]. Mutations
in Nsdhl are found in the Bare patches (Bpa) and Striated (Str) mice
[35]. Analysis of tissue samples from Bpa/Str females showed an
accumulation of 4-methyl and 4,49-dimethyl sterol intermediates.
Human mutations in EBP cause X-linked dominant chondrodys-
plasia punctata (CDPX2, Conradi-Hunermann syndrome [36]).
Patients with CDPX2 usually have normal plasma total cholesterol
levels but increased levels of other sterols, including 8-dehydro-
cholesterol and cholesta-8(9)-en-3b-ol [36,37,38,39]. Tattered (Td)
carries a missense mutation in the Ebp gene and phenotypically
resembles the rudolph mutation most among all the known
cholesterol biosynthetis mouse mutants. Male Td embryos die
between E12.5 and birth and have defects in the skeleton and
brain similar to those we describe here [40]. The sterol profile of
heterozygous female mice includes elevated 8-dehydrocholestrol
and choles-8(9)-en-3b-ol. All of these findings combined with our
data suggest a model in which the accumulation of specific sterols
leads to the defects we observe. One of the effects these inhibitory
sterols may be to dampen the intracellular response to Shh
signaling.
Rudolph mutants show similarities to other loss-of-
function Shh phenotypes
Although rudolph mutants lack some of the classic features of the
Shh null mice, such as holoprosencephaly, other more specific
ablations of SHH signaling have some features resembling the
rudolph phenotype. In particular, the skeletal defects we observe in
the rudolph mutant are similar to those described in the Indian
hedgehog (Ihh) and dispatched-1 (Disp1) loss of function mice and the
conditional ablation of Smo from the developing skeleton
[41,42,43]. As Ihh is the most active Hh ligand in development
of long bones, we suggest that the similarities between rud and the
HH-signaling mutants reflect the conservation of intracellular
signaling transduction mechanisms between the different Hh
ligands, and that these defects are due to an insufficient response
to secreted IHH in the cartilage. In addition, the disorganized
retina in rud mutants also resembles that seen in embryos with an
ablation of Shh using a Thy1-Cre [44]. The role of Shh and Ihh as
mitogens in retinal neuroblast proliferation has been established
[45], and Shh, Ihh and Gli1 are expressed in retina at E12 and E13
[44,46]. The difference in timing between the cortical and retinal
defects (rudolph retinal molecular defects are seen at E14.5, but not
E12.5, Figure S4) is consistent with the later expression pattern of
Shh signaling components in the retina as compared to forebrain
tissue.
The developing rudolph forebrain phenotype has both similarities
to and differences from the known effects of Shh loss of function.
The decreased cell proliferation and increased apoptosis we find
are completely consistent with a role for Shh as a mitogen for the
developing neural tissue and with the observations that blocking
SHH function can lead to cell death [47], and that conditional
ablation of Smo throughout the cortex by E9 using the Foxg1-Cre
leads to increased cell death [48]. Emx1-Cre ablations of Shh and
Smo in the dorsal telencephalon by E10 cause a smaller
telencephalon featuring reduced proliferation and neuronal
differentiation with increased cell death [49]. However, the
Figure 5. Sonic hedgehog signal transduction is abnormal in rudolph embryonic nervous system and cells. (A–D) Rudolph-Patched lacZ
embryos at E11.5 (A,B) and E14.5 (C,D) show less Ptc-lacZ activity in rudolph mutant brain tissue (B,D) as compared to wild-type (A,C). Asterisks in B
indicate the midbrain in the mutant where Ptc-lacZ is particulary reduced compared to wild-type. Section in situ hybridization shows less Gli1
expression in the rudolph retina at E14.5 (F) than in wild-type (E).
doi:10.1371/journal.pgen.1002224.g005
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PLoS Genetics | www.plosgenetics.org 9 September 2011 | Volume 7 | Issue 9 | e1002224Figure 6. Sonic hedgehog signal transduction is abnormal in rudolph skeletal elements. (A,B) Embryos from a mixed background show an
incompletely penetrant limb patterning defect. Whole mount in situ hybridization shows a Ptc domain in the posterior portion of the developing
wild-type limb bud (C), which can be lost in rudolph mutants (D). Hedgehog signaling is also decreased in the developing long bones of rudolph
mutants (F,H) compared to wild-type (E,G) as shown by Ptc-lacZ (E,F) or section in situ hybridization (G,H).
doi:10.1371/journal.pgen.1002224.g006
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more a loss of polarity phenotype, such as the cortical ablation of
numb and numb-like [50]. Because Shh loss of function has not been
demonstrated to directly affect polarity, we suggest that abnor-
malities of cortical signaling mechanisms other than Shh must be
disrupted in the rudolph cortex to explain some of the develop-
mental abnormalities of the CNS we observe. Because cortical
dysplasia is not characteristic of any of the known human disorders
of cholesterol biosynthesis, the extremely high CNS level of
zymosterone, normally only a trace sterol in the brain, suggests
that zymosterone or other 3-ketosterols in the rud brain could have
a direct toxic effect or could otherwise impair neuronal
differentiation.
Rudolph is a hypomorphic allele of Hsd17b7
Two reports have recently described the phenotypes of Hsd17b7
null allele mice [18,19]. These embryos have major morphological
abnormalities by E10.5, precluding direct comparison to the
Figure 7. Sonic hedgehog signal transduction is abnormal in rudolph cells. In vitro analysis also shows a decreased response to hedgehog
protein in mouse embryonic fibroblasts (MEFs). Wild-type, but not mutant, MEFs show increased cell growth upon treatment with SHH (A; *p=0.001
for wt; n=4). Quantitative RT-PCR analysis also shows a reduced response of Gli1 (B; *p=0.002 for wt, p=0.01 for rud; n=3) and Patched (C; *p=0.001
for wt; n=3) upon SHH treatment in mutant MEFs. b-galactosidase accumulates in SHH-treated wild-type;Ptc-lacZ MEFs, but not rud;Ptc-lacZ MEFs (D;
*p=0.005 for wt; n=4). (E) PzP53Med (Ptc-lacZ;p53 medulloblastoma) cells infected and clonally selected with control plKO.1 lentivirus respond to
SHH treatment with accumulation of b-galactosidase (* p=0.07 for wt; n=4). Two independent clonal lines infected with Hsd17b7 RNAi constructs do
not respond as robustly to SHH treatment.
doi:10.1371/journal.pgen.1002224.g007
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Hsd17b7 homozygous null embryos, and development does not
proceed past E9.5. A sterol analysis performed in these mutants
demonstrated increased Hsd17b7 enzyme substrates and un-
changed cholesterol levels, similar to the results we report [19].
Maternal supply of cholesterol was also suggested to account for
the normal embryonic cholesterol levels. Expression of Shh and Ptc
was examined in the Hsd17b7 homozygous null embryos at E8.5,
but the domain and levels of expression did not differ from wild-
type [19].
The phenotypic differences between the rudolph and Shh mutants
may be due to the hypomorphic nature of the rudolph allele.
However, we also note that the rudolph phenotype in the CNS
begins to emerge around E12.5, which is the time when the blood-
brain barrier forms and synthesis of cholesterol within the CNS
becomes separated from non-neural cholesterol synthesis
[51,52,53,54]. The developmental consequences of reduced sterol
concentrations in the early embryo could be mitigated by the
maternal circulation in view of evidence that, in rodents,
substantial amounts of maternal cholesterol can be transported
to the fetus through the placental-fetal interface [55], thus possibly
compensating for a lack of early Hsd17b7 function in the initial
patterning stages of embryonic development. We therefore
propose that formation of the blood-brain barrier creates a
neurodevelopmental compartment absolutely requiring endoge-
nous Hsd17b7 function, which, when absent, results in the severe
phenotypes we describe here.
Sterols in Hh signaling
Perhaps the most intriguing aspect of this study is that it is the
first in vivo validation of several recent studies suggesting an
intracellular role for sterols in SHH signaling [8,11,12]. These
cholesterol intermediates have been demonstrated to have a role
in the transduction of HH ligand signaling as well as the
subcellular localization of HH signaling components. The fact
that the mutant MEFs demonstrate normal Smoothened
localization to the cilium, but a compromised response to SHH
ligand, suggests that normal sterol concentrations are required for
proper activation of Smoothened [6]. Alternatively, an inhibitory
sterol may be present at increased levels, preventing the
activation of the pathway.
Treatment with statins is a well-accepted method for lowering
cholesterol levels in human patients by inhibiting HMG-CoA
reductase (Hmgcr), the rate-limiting step in cholesterol biosynthe-
sis. Statin treatment could also have significant effects on local
concentrations of oxysterols generated from intermediates in the
cholesterol biosynthetic pathway further downstream. Mouse
Hmgcr mutants, which should genetically mimic a total block in
the pathway at the site of action of statins, are not viable past
implantation [56] and are therefore not informative in this
regard. It will be important to study further the role of
cholesterol intermediates and metabolites in various physiolog-
ical settings and signaling paradigms. In doing so, we may find
that statin treatments may be having unintended consequences
i nh u m a nh e a l t hi ns i t e so fa d u l tHh activity, including adult
neurogenesis.
Materials and Methods
Mouse husbandry and genotyping
Rudolph mice were originally generated by ENU mutagenesis of
A/J mice and then outcrossed to FVB/J mice (both obtained from
Jackson Labs, Bar Harbor, ME). Initial mapping was done with a
whole genome SNP panel similar to one we previously described
[17], and the mutation mapped to a 19.6 Mb interval on
chromosome 1. Exon directed sequencing (including some
flanking intronic sequence to identify mutations potentially
affecting splicing) identified the rudolph mutation. Genotyping is
done with either D1Mit454 or D1Mit524 microsatellite markers
depending on strains involved. We maintained the colony with a
combination of intercrossing and outcrossing to FVB. The
C57BL/6J Ptc1-lacZ mouse was obtained from the Jackson
laboratory and intercrossed with rud heterozygous mice;Ptc1-lacZ
genotyping was done with standard lacZ primers. We have also
performed backcrosses of the rud allele to mice on C57BL/6J and
129X1/SvJ backgrounds. All animals were housed in accordance
with the Harvard Medical School ARCM regulations. Timed
matings were checked for signs of copulation in the morning;
vaginal plugs were noted and noon of that day was established as
embryonic day (E) 0.5.
Histology and immunohistochemistry
Embryos used for histological analysis were fixed with Bouin’s
fixative for at least forty-eight hours and processed for paraffin
embedding using a Leica TP1020 automated tissue processor.
Sections were cut at a thickness of 14 mm and stained with
hematoxylin and eosin using standard techniques. Microscopy was
done with a Leica DC500 or Zeiss AxioImager with ApoTome.
TUNEL assay was performed with the In Situ Cell Detection Kit,
TMR Red, following the manufacturer’s instructions (Roche).
BrdU labeling was done with a BrdU Labeling and Injection Kit
(Roche). The TuJI antibody (SIGMA) was used at 1:500 for
2 hours at room temperature on paraffin sections with citrate
buffer antigen retrieval. Neural tube immunohistochemistry was
performed using standard methods with antibodies from the
Developmental Studies Hybridoma Bank.
Skeletal measurements
To measure the size of the skeletal elements, embryos were stained
for cartilage and bone using standard methods [57] and photo-
graphed. The length of each element was calculated using NIH
Image J software, and units were converted to mm using standards.
In vitro analysis of SHH signaling
Mouse embryonic fibroblasts were generated using standard
methods and plated at a density of 20,000 cells/cm
2 in the
presence or absence of 200 ng/mL SHH amino terminal peptide
(R&D Systems). Cell number was determined with the CyQuant
Cell Proliferation Assay (Invitrogen), and b-galactosidase produc-
tion was measured with the Galacto-Light Plus System (Applied
Biosystems). Assays were performed 48 hours after plating. Cell
growth experiments were done with an initial culture of 6,000 cells
in a 96-well plate.
Figure 8. SMO-GFP localization to the primary cilium is not affected in rudolph mutant MEFs. Wild-type (A–I) and rudolph (J–R) mutant
MEFs were transfected with a SMO-GFP plasmid and acetylated a-tubulin immunocytochemistry was used to identify the primary cilium. SMO-GFP in
untreated cells is seen outside the cilium (A–C, J–L), accumulating at the base of the axoneme (not shown), or throughout the cilium (D–F, M–O).
Treatment with SHH protein localizes SMO-GFP throughout the cilium in the majority of cells observed (G–I, P–R). All images were taken at the same
magnification and the scale bar in C represent 10 mm.
doi:10.1371/journal.pgen.1002224.g008
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Lentiviral particles were made via transfection of 293T cells
with plasmids including a plKO.1 control and a validated RNAi
construct against mouse Hsd17b7 (Open Biosystems, Huntsville,
AL; clone TRCN0000041646). PzP53Med cells [20] were infected
with 293T supernatant containing lentivirus. After puromycin
selection, resistant cells were plated at clonal density and
individual clones were isolated, maintained and analyzed with
qRT-PCR for Hsd17b7 levels. Control and knock-down clones
were treated with SHH protein as described above.
RT-PCR analysis
Total RNA from either brains or MEF cultures was prepared
with TRIZOL (Invitrogen) and cDNA was made with qScript
cDNA synthesis kit (Quanta) or the SuperScript RTIII system
(Invitrogen). Hsd17b7 transcripts were analyzed with both random
hexamer primed cDNA and gene specific primed cDNA synthesis
(primer: TTTTGGTACCTCAGCTCGGGTGATCCGATTT-
CTG). Hsd17b7 transcripts were analyzed with primers amplifying
exons 6–8 (F: TCTGTATTCCAGTGTGATGTGC; R: CT-
TTTGGCCCGTGACGTAAT; 259 bp) or exons 6–7 (F:
TCTGTATTCCAGTGTGATGTGC; R: CCACATTATGGG-
TAGGAGCAA ; 100 bp). Quantitative RT-PCR was done on a
BioRad iCycler using either total RNA with Taqman probes
(Applied BioSystems) or cDNA with Perfecta SYBR Green




CACTCACGGCAAATTC), and Gapdh-R (TCTCCATGGTGG-
TGAAGACA).
In situ hybridization and LacZ staining
Section mount in situ hybridization was done as previously
described [58] with hybridization at 60 degrees and with BM
Purple (Roche) for visualization of riboprobes. Probes used are
published: Gli1 [59] and Ptc [60]. Embryos were stained with lacZ
using standard protocols [57] and then processed for paraffin
histology as described above. Older embryos were fixed in 4%
paraformaldehyde, cryoembedded in OCT, sectioned at 20 mm
and stained on slides.
Westerns
Embryos were homogenized in 1% SDS Lysis Buffer and
protein extracts were run on a 10% polyacrylamide gel. A rabbit
polyclonal antibody was used for Hsd17b7 (1:1000, overnight at 4
degrees C), and a mouse monoclonal anti-actin antibody (1:5000,
SIGMA, 60 minutes at room temperature) was used as a loading
control.
GFP fusion proteins and transfections
Full-length mouse Hsd17b7 from wild-type and mutant tissue
was initially cloned into a pENTR/D/TOPO vector (Invitrogen)
and then into the pcDNA-DEST47 vector (Invitrogen). DNA for
either Hsd17b7-GFP or rud-GFP was co-transfected with Sec61b-
mCherry (gift of T. Kirchhausen) into NIH3T3 cells using Fugene
(Roche) following manufacturer’s instructions. 48 hours after
transfection, cells were fixed with 4% paraformaldehyde and
counter-stained with DAPI. SMO localization within ciliated
MEFs was observed by transfection of 20–30% confluent MEFs
plated on 0.4% gelatin or poly-lysine coated coverslips in 24-well
plates with the pBabePuro-A1:Smo:GFP plasmid ([9], gift of A.
McMahon). Confluent cells were treated overnight with SHH
peptide 48 hours after transfection. Immunocytochemistry was
done by fixing with 4% paraformaldehyde/0.2 TritonX-100 for
20 minutes and blocking with 1% BSA for 60 minutes. Antibodies
used were acetylated a-tubulin (SIGMA) at 1:2000 for 60 minutes
at room temperature and Goat anti-mouse Alexa Flour 594
(Invitrogen) at 1:500 for 30 minutes at room temperature. Cells
were mounted with VectaShield (Vector Laboratories) and imaged
on a Zeiss AxioImager.
Sterol analysis
Sterols were extracted from brain tissue as previously described
with the addition of sterol-specific ions for the compounds of
interest to this study [61]. Sterol levels are reported as a fraction of
total sterols.
Supporting Information
Figure S1 Variable Phenotypes of the Rudolph Mutant. In many
mutants, the precursor to the nasal blood spot seen in late
embryogenesis can be seen as a blebbing of the nasal epithelium
as early as E12.5 (A). Introduction of the B6 genetic background
to the colony resulted in some animals having more severe
blebbing, which spreads beyond the tip of the snout (E18.5 in B,
E12.5 in C). (E) The effect of the rudolph mutation on the splicing
pattern of the Hsd17b7 cDNA (PCR reaction spanning exons 6–8)
does not change among tissues (heart/lung, limbs, or brain) from
wild-type (w), heterozygous (rud/+; h) or mutant (rud/rud;m ) .
cDNA obtained from embryos on the C57BL6 background
(whole embryo: B6) or from B6 brain shows the same pattern of
splicing.
(TIF)
Figure S2 Measurements of the long bones in both the forelimbs
and hindlimbs at E16.5 and E18.5 show that mutant appendicular
skeletal elements are significantly shorter at both stages.
(TIF)
Figure S3 Rudolph mutants have phenotypes throughout the
CNS. Disorganized neural tissue is seen in the neural tube (B) at
E16.5. Analysis of the forebrain at E12.5 shows grossly normal
organization of the mutant brain (D) but some disorganization of
cortical tissue is apparent (F).
(TIF)
Figure S4 The rudolph mutant form of Hsd17b7 protein is
unstable. NIH3T3 cells were transfected with either wild-type
Hsd17b7-GFP plasmid or a construct lacking the seventh exon to
mimic the rudolph mutation (rud-GFP). Co-transfection with a
Sec61-bmCherry plasmid serves to identify the endoplasmic
reticulum (ER). Wild-type Hsd17b7-GFP is found in the (ER) as
expected (A–C). Expression of the rud-GFP results in little or no
GFP expression (D–F).
(TIF)
Figure S5 Sonic hedgehog signaling in rudolph mutants. Patched-lacZ
expression in rudolph;Ptc-lacZ brain (B) is weaker at E14.5 than in
wild-type;Ptc-lacZ embryos (A). Gli1 expression in developing
brain is also weaker in mutants (D) as compared to wild-type (C).
(TIF)
Figure S6 Neural tube patterning is normal in rudolph mutants.
Immunohistochemical analysis in the neural tube at E10.5 (A–N)
and E12.5 (O–BB) for a variety of cell fates along the dorsal-
ventral axis show no changes in patterning between wild-type and
rudolph mutant embryos.
(TIF)
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wild-type and rudolph embryos were prepared and the length of the
skeletal elements were measured in Image J and converted to mm.
(DOC)
Table S2 Mutant and phenotype incidence. Embryos were
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